MAS
PCVX icon

Meeder Advisory Services’s Vaxcyte PCVX Stock Holding History

Meeder Advisory Services’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Sell
7,785
-550
-7% -$29.9K 0.02% 450
2026
Q1 		$484K Buy
8,335
+231
+3% +$12.5K 0.02% 400
2025
Q4 		$374K Buy
8,104
+2,286
+39% +$102K 0.02% 456
2025
Q3 		$210K Buy
+5,818
New +$193K 0.01% 589

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Meeder Advisory Services's PCVX Position: Q2 2026 in Review

Meeder Advisory Services reduced its Vaxcyte (PCVX) stake by 6.6% in Q2 2026, selling an estimated $29.9K and leaving 7,785 shares worth $453K. The position accounts for 0.02% of the portfolio, ranked #450.

Meeder Advisory Services first reported a position in PCVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $484K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Meeder Advisory Services held 7,785 shares of Vaxcyte worth $453K as of Q2 2026.
  • Meeder Advisory Services sold 550 Vaxcyte shares in Q2 2026, an estimated $29.9K.
  • Vaxcyte made up 0.02% of Meeder Advisory Services's portfolio in Q2 2026, its #450 holding.
  • Meeder Advisory Services first reported a position in Vaxcyte in Q3 2025 and has held it in 4 quarters since.
  • Meeder Advisory Services's Vaxcyte position peaked at $484K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.